Nothing to do with smoke and mirrors, this is the data behind the initial ASX announcements re the trial outcomes. If you are under 65 and in ICU on a respirator with COVID ARDS remestemcel-L makes a distinct difference to whether you live or you die, fairly simple. Just not much difference yet if you are over 65, except for the first 7 days.
How the ages of people who entered the trial increased is also much clearer, as are all the other treatments that appeared along the way.
Nothing negative just the background data. Probably too much information for some.
Ann: COVID ARDS Trial Respiratory Outcomes Presented, page-21
-
- There are more pages in this discussion • 143 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $18.15M | 12.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3418 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 24361 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |